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Abstract: Coronary computed tomography angiography (CCTA) may 
improve the diagnosis and management of acute and stable chest pain syn-
dromes. The key for caregivers of patients presenting with acute chest pain 
is the early identification and management of life-threatening conditions, 
such as acute coronary syndromes, pulmonary embolism, and acute aortic 
dissection. The main goal in stable chest pain syndromes is to determine the 
extent and severity of coronary artery disease. This review article will criti-
cally evaluate the current literature supporting the evidence for the clinical 
use of CCTA in acute and stable chest pain syndromes, considering the latest 
innovations in CCTA technology and their potential impact on patient care.
Key Words: acute chest pain syndrome, stable chest pain syndrome, 
computed tomographic angiography
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ACUTE CHEST PAIN SYNDROME
Epidemiology
In the United States, more than 7 million patients are admitted 
to the emergency department (ED) each year with acute chest pain as 
their main complaint, making it one of the most frequent causes of 
ED visits.1 However, only 2–8% of those patients are diagnosed with 
an acute coronary syndrome (ACS).2 The remainder of patients are 
diagnosed with noncardiac etiologies, including pulmonary, vascular, 
gastrointestinal, and musculoskeletal causes.
ACS includes acute myocardial infarction (AMI), encompassing 
both ST-elevation myocardial infarction (STEMI) and  non-ST segment 
myocardial infarction (NSTEMI), and unstable angina pectoris (UA).3,4 
The presence of an STEMI is usually identified on initial electrocardio-
gram (ECG), whereas UA and NSTEMI require further clinical evalua-
tions. UA is defined as chest pain due to ischemia without the presence 
of myocardial necrosis, whereas NSTEMI requires the presence of 
myocardial necrosis, manifested by troponin elevation. It should be 
noted that UA and NSTEMI are therefore indistinguishable until serial 
troponin or other biomarkers of myocardial injury are assessed.4,5
The pathophysiology leading to ACS is classically due to 
rupture of an atherosclerotic plaque (approximately 60%) or plaque 
erosion (approximately 40%),6,7 followed by subsequent thrombus for-
mation and obstruction of coronary blood flow to downstream coro-
nary segments. These “high-risk” culprit plaques are morphologically 
characterized by a large lipid/necrotic core, thin fibrous cap, high 
density of macrophages, and potentially small calcified embedded 
nodules.6 They may not necessarily be associated with severe luminal 
stenosis, which may explain why no significant lesions are identified 
by standard invasive angiogram for 5–20% of events.6,8 Alternatively, 
ACS can be developed in the setting of significant luminal narrow-
ing due to stenosis progression, with either reduced downstream blood 
flow and oxygen supply or increased myocardial demand. Rarer causes 
of ACS with distinctly different pathophysiological mechanisms 
include coronary vasospasm and microvascular dysfunction of the 
myocardium.9
The Immediate Value of Coronary  
Computed Tomography Angiography in  
Acute Chest Pain Syndrome
A traditional diagnostic work-up of acute chest pain (Fig. 1) 
includes an initial clinical assessment and determining whether the 
patient is suffering from ACS; determination is done by patient’s his-
tory, physical examination, 12-lead ECG, and laboratory findings, 
such as cardiac biomarkers.4 Patients with high-risk findings can be 
readily diagnosed and referred for invasive diagnosis and treatment. 
Low-risk patients can be readily discharged for outpatient  follow-up. 
However, a large proportion of patients remain in the ED or in a 
dedicated chest pain unit until ACS can be reliably ruled out. These 
patients undergo serial cardiac biomarkers and ECG testing during 
the next 24 hours, frequently followed by a stress test for risk strati-
fication, if subsequent ECG and biomarkers tests are inconclusive. 
Although the number of missed ACS events can be reduced with this 
common strategy, it leads to increased test burden, length of hos-
pitalization, and prolonged stay in the chest pain unit. Despite the 
conservative triage practice, 2–3% of all patients suffering from ACS 
within 72 hours of ED presentation are erroneously discharged, con-
tributing to the fact that missed ACS is the number one cause for ED 
malpractice costs in the United States.10,11
To overcome these problems, early coronary computed tomog-
raphy angiography (CCTA) has been suggested to be a safe, fast, and 
cost-effective modality. In addition, CCTA facilitates early triage of 
acute chest pain patients in the ED and has been recognized as a 
viable alternative to the traditional standard of care. This is the result 
of several studies including more than 3000 patients which have been 
conducted to evaluate CCTA for the triage of patients presenting to 
the ED (Table 1), which are discussed in detail below.
Diagnostic Accuracy of Coronary  
Computed Tomography Angiography for  
Acute Coronary Syndrome
Over the last few years, CCTA has evolved into a dependable 
tool for the assessment of coronary artery disease (CAD). In particu-
lar, with the introduction of 64-slice scanners in 2003, the temporal 
and spatial resolution reached a sufficient level to reliably determine 
the presence of obstructive atherosclerotic disease. A meta-analysis 
including 18 studies, which compared 64-slice CCTA with invasive 
angiography, demonstrated good diagnostic accuracy of CCTA for 
obstructive CAD although specificity was limited due to artifacts and 
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anatomical severity of stenosis was variably associated with hemody-
namic significance.12 Similarly, the probability in detecting any CAD 
by CCTA reached more than 90% if the plaque’s maximal intimal 
thickness was more than 1 mm, as measured by intravascular ultra-
sound.13 CCTA also allows the assessment of left ventricular (LV) 
morphology and function, myocardial perfusion, and quantitative 
plaque and stenosis measurements.14
In 2007, Rubinshtein et al15 found in 58 patients with acute 
chest pain and the absence of new ECG changes or elevated 
biomarkers that CCTA-based assessment of obstructive CAD has a 
high sensitivity (100%) and specificity (92%), with good positive pre-
dictive values (PPVs) and excellent negative predictive values (NPV) 
(87% and 100%, respectively) for ACS. Furthermore, they suggested 
that CCTA may allow for a safe and early discharge, because no 
death or AMI occurred among those who were directly discharged 
from the ED based on CCTA results. These initial findings were sub-
stantiated and extended by a larger prospective observational cohort 







No. Controls Subjects Intervention Control Outcome of Interest
Observed Difference 
(CCTA vs. Control)
Goldstein et al33 2007 179/1 Negative troponin
Nondiagnostic ECG
Age: 49 ± 12 yr
Female: 50%














Goldstein et al30 
(CT-STAT)
2011 749/16 Negative troponin
Nondiagnostic ECG
Age: 50 ± 10 yr
Female: 54%
CCTA MPI Prevalence of AMI









2.9 hr vs. 6.2 hr
7% vs. 6%
$2137 vs. $3458
12 mSv vs. 13 mSv
Litt et al32 2012 1370/5 Negative troponin
Nondiagnostic ECG
Age: 49 ± 10 yr
Female: 53%














Hoffmann et al31 
(ROMICAT II)
2012 1000/7 Negative troponin
Nondiagnostic ECG
Age: 54 ± 8 yr
Female: 47%










5.8 hr vs. 21.0 hr
11% vs. 7%
$2101 vs. $2566
14 mSv vs. 5 mSv
The work-up in the ED using CCTA was compared either to a work-up strategy requiring nuclear MPI or to a traditional SOC work-up strategy.
*Significant difference (P < 0.05).
†Estimated from presented data.
AMI indicates acute myocardial infarction; CCTA, coronary computed tomography angiography; ECG, electrocardiogram; ED, emergency department; MACE, major adverse 
coronary events; MPI, myocardial perfusion imaging; mSv, millisievert; ROMICAT, Rule Out Myocardial Infarction using Computer-Assisted Tomography; SOC, standard-of-care; 
STAT, Systematic Triage of Acute Chest Pain Patients to Treatment.
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Tomography (ROMICAT I) trial published in 2009,16 which evalu-
ated the potential of CCTA for the triage of patients with acute chest 
pain in the ED. This trial is the only study in which the CCTA results 
remained blinded to the caregivers and patients. Therefore, the diag-
nostic performance of CCTA for ACS and its association with other 
test findings could be studied in a truly unbiased manner. The trial 
included 368 patients from the ED with acute chest pain with an ini-
tial inconclusive assessment. CCTA detected no evidence of CAD in 
roughly half of the cohort, whereas approximately 20% were found 
to have obstructive CAD. The absence of CAD by CCTA accurately 
predicted the absence of ACS (100% NPV), and obstructive CAD 
(>50% luminal narrowing) was associated with 77% sensitivity and 
87% specificity for ACS.16 Not surprisingly, the presence and extent 
of coronary plaque and stenosis were superior in their discrimina-
tive capacity for ACS, as compared with clinical risk scores such as 
Thrombolysis In Myocardial Infarction (TIMI) or Goldman.17
Studies also demonstrated that the mere detection of obstruc-
tive CAD by CCTA does not equate to a diagnosis of ACS. For 
example in the ROMICAT I trial, 20 of 34 patients with obstructive 
CAD had ACS;16 in a trial by Hollander et al,18 only 7 of 54 patients 
with obstructive CAD in CCTA had a stenosis on invasive coronary 
angiography (ICA) or developed a major adverse coronary event 
(MACE) within 30 days. Combined with the low prevalence of ACS 
in population with acute chest pain (2–8% have ACS), CCTA shows 
a low PPV for ACS (approximately 35–50%). Further reduction of 
specificity may occur based on the reliance of CCTA on morphol-
ogy and on the definition of significant stenosis, as not all luminal 
narrowing of more than 70% are hemodynamically significant when 
compared with fractional flow reserve (FFR).12
To improve the PPV of CCTA for ACS, different strategies 
have been evaluated:
1. Assessing global and regional LV function. The results demon-
strated that the presence of regional LV dysfunction incremen-
tally and independently improves the diagnostic accuracy for ACS 
beyond morphological evaluation of coronary arteries in patients 
with CAD (sensitivity of coronary stenosis versus coronary steno-
sis and LV dysfunction for ACS: 77% versus 87%, respectively).19 
However, the assessment of LV function comes with the expense 
of radiation and excludes the application of novel computed to-
mography (CT) acquisition protocols, see below.
2. Detailed plaque assessment. For example, if more than 1 steno-
sis was to be found, it would subsequently increase the PPV.16 
Furthermore, a score based on plaque morphology, including low 
CT attenuation, length of stenosis, and positive remodeling, re-
sulted in a PPV of 100% for ACS in patients with obstructive le-
sions.20 In other studies, plaque morphology, in particular the triad 
of low attenuation plaque (signifying a lipid-rich necrotic core), 
positive remodeling, and spotty calcification, has been shown to 
be associated with culprit lesions. More recently, the “napkin-ring 
sign” has been described as the most specific CT plaque morphol-
ogy sign for the identification of fibroatheroma, with a large ne-
crotic core or potentially high-risk plaques.21 However, the assess-
ment of plaque morphology is not routinely performed in clinical 
practice and further data are needed to support these findings.
3. Evaluation of myocardial perfusion. In an observational study by 
Feuchtner et al,22 76 patients with acute chest pain in an ED set-
ting underwent CCTA, including assessment of myocardial perfu-
sion abnormities. Although the PPV for the presence of stenosis in 
this selected cohort was 67%, it increased to 90% when CT-based 
myocardial perfusion information was added. This is supported 
by other small ED studies.23 Results from experimental studies 
showed a good correlation of CT-based rest and stress myocar-
dial perfusion imaging (MPI) with in-vivo reference standards.24 
However, this new CT application, especially the value of resting 
myocardial perfusion in the acute setting, warrants further investi-
gation before its clinical value can be fully determined.
In summary, the absence of CAD determined by CCTA is 
observed in 50% of population with acute chest pain presented in 
the ED, providing an NPV (for ACS) of approximately 100%. In con-
trast, obstructive coronary disease, as determined by CCTA, is asso-
ciated with ACS during index hospitalization. The PPV for ACS can 
be improved by additional assessments, such as regional LV dysfunc-
tion, plaque morphology, or myocardial perfusion. As a result, CCTA 
has a class IIa, level of evidence B recommendation for the evalua-
tion of patients with acute chest pain with a low–intermediate pretest 
probability of ACS and inconclusive initial ECG and biomarkers.25,26
Coronary Computed Tomography Angiography 
for the Simultaneous Rule-Out of Acute Coronary 
Syndrome, Pulmonary Embolism, and Acute Aortic 
Syndrome
Acute chest pain syndromes also include 2 other common 
and life-threatening diagnoses: pulmonary embolism and acute aor-
tic syndrome. Triple rule-out CT angiography protocols have been 
developed to simultaneously provide sufficient contrast enhancement 
of the thoracic aorta, coronary arteries, and pulmonary arterial cir-
culation.27 Compared with CCTA, more iodinated contrast agent is 
needed to account for the transit time between pulmonary and aorta/
coronary opacification (approximately 10 s), and the scan coverage is 
lengthened as the entire thorax needs to be assessed. Similar to dedi-
cated CCTA, the use of advanced CT technology with dose-saving 
acquisition algorithms has significantly lowered the exposure result-
ing from triple rule-out protocols.27
Several studies have demonstrated the clinical feasibility and 
high accuracy of a triple rule-out CT protocol.28,29 Based on this 
limited evidence, a triple rule-out protocol may be most appropriate 
for patients presenting with undifferentiated acute chest pain and at 
low–intermediate risk for ACS. In these patients, traditional work-up 
includes stress testing to rule out ACS, which is often followed by an 
initial CTA for pulmonary embolism. However, the precise clinical 
indications and the appropriate patient population in which the triple 
rule-out CTA may be preferable to traditional work-up remain unclear.
Change in Patient Management
CCTA use in the setting of patients with chest pain and at low–
intermediate risk presenting to the ED may have a large impact on 
patient management. One of the major drawbacks of the standard tri-
age, including stress testing, is the extended hospitalization for serial 
biomarkers, ECG, and risk-stratification testing (Fig. 1). Based on 
the fact that 50% of this population has no CAD, it seems that CCTA 
could significantly and safely reduce the duration of the hospital stay 
(Fig. 2). Four large, multicenter, randomized trials have tested these 
hypotheses (Table 1).
In the Coronary Computed Tomographic Angiography for 
Systematic Triage of Acute Chest Pain Patients to Treatment trial by 
Goldstein et al,30 749 patients with acute chest pain but negative ECG 
and initial biomarkers were randomized to early CCTA or to rest-
stress single-photon emission computed tomographic myocardial 
perfusion imaging (SPECT-MPI). The CT-based strategy reduced 
the time to diagnosis when compared with the SPECT-MPI, by more 
than 50% (2.9 versus 6.2 hours). CCTA was also associated with a 
reduced radiation exposure when compared with SPECT-MPI, with 
similar MACE rates at a 6-month follow-up for patients directly dis-
charged from the ED (0.8% for CCTA versus 0.4% for SPECT-MPI).
The recently published ROMICAT II trial by Hoffmann et al31 
compared 2 management strategies in low–intermediate risk patients 
with acute chest pain—one including early CCTA as a first diag-
nostic test. This was performed versus standard-of-care (SOC) ED 
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evaluation, which included all options of stress testing or no testing. 
They found a shorter length of stay (18 versus 25 hr) in the CCTA 
strategy, driven by a higher rate of direct discharge from the ED (50% 
versus 22%). The third trial published by Litt et al32 enrolled 1370 
subjects, of which 908 were in the CCTA group and 462 in the SOC 
group. The main objective of this trial was to establish safety of CCTA 
discharge, as defined by an upper 95% confidence interval (CI) less 
than 1% for missed ACS or death during the 30-day follow-up.
There is a concern that CCTA may lead to a higher number of 
secondary diagnostic testing, such as cardiac catheterizations. In a 
randomized, controlled trial published in 2007 by Goldstein et al,33 
24 of 99 patients had either “stenosis of unclear significance” or 
unevaluable segments, requiring a stress myocardial perfusion scan, 
21 of which showed no perfusion defect. The cumulative rate of 
cardiac catheterization was 12% for the CCTA strategy versus 7% 
for SPECT-MPI. Recent studies have yielded similar results. In the 
ROMICAT II trial (total N = 1000),31 the rate of cardiac catheteriza-
tion was 11% in the CCTA group versus 7% in the SOC groups (P = 
0.06). A total of 27% were referred for a second diagnostic test after 
an initial CCTA, significantly more than in the SOC group.
In summary, usage of CCTA in the early phase of managing 
patients with acute chest pain reduces the total length of stay but may 
increase downstream testing. In a recent meta-analysis by Hulten 
et al,34 an absolute increase in invasive angiography after CCTA of 21 
(95% CI, 2–45) per 1000 CCTA scans was determined. Similarly, the 
rate of revascularizations increased by 20 (95% CI, 5–41) per 1000 
CCTA scans. Unfortunately, neither LV function nor myocardial perfu-
sion nor advanced plaque assessment for further evaluation regarding 
hemodynamic significance were used to guide patient management 
in these trials. Whether increased percutaneous coronary intervention 
rates after CCTA may result in improved  long-term health outcomes 
is possible but has not been established yet. In addition, FFR was not 
used in a standardized manner during invasive angiography in any of 
these trials. It remains unclear how far novel biomarkers such as high-
sensitivity troponin could provide a similar outcome as compared with 
CCTA if used as gatekeepers in patients with acute chest pain syn-
drome presenting to the ED. Despite these shortcomings, CCTA has 
been established as a viable alternative to standard functional testing.
The Long-Term Value of Coronary  
Computed Tomography Angiography in  
Patients With Acute Chest Pain
The presence and extent of CAD are universally recognized 
as the strongest predictors of future coronary events.35 Similarly, 
this information acquired from the CCTA scan may have prognos-
tic value in patients with acute chest pain. The 2-year follow-up of 
the ROMICAT I trial published by Schlett et al36 observed MACE in 
5 of 300 patients (1 STEMI, 3 NSTEMI, and 4 percutaneous coro-
nary intervention (PCI)) without ACS during index hospitalization. It 
should be noted that 4 of 5 events occurred in patients with obstruc-
tive CAD detected by CCTA. The estimated 2-year event rate for late 
MACE (>30 days) was 0% for no CAD, 1.2% for nonobstructive CAD, 
and 8.9% for obstructive CAD (P < 0.0003). The presence of LV dys-
function on CCTA also provided incremental value for the long-term 
prognosis (estimated 2-year event rate for late MACE for patients with 
obstructive CAD and regional LV dysfunction was 18.5%).
The evidence that patients with acute chest pain without CAD 
on CCTA remain event free over a long period was further supported 
by a study by Sozzi et al,37 where 222 patients were followed for 
a mean of 5 years. In those patients without the evidence of CAD, 
no one developed MACE. Conversely, the annual reported event 
rate was 1.2% for patients with nonobstructive CAD and 4.2% with 
obstructive CAD. Similar findings were observed in a registry study 
(median follow-up, 13 months),38 where patients with acute chest 
pain at low to intermediate risk for CAD underwent both calcium 
scoring and CCTA. Out of 458 patients, without evidence of ACS 
at discharge, 70 (15%) experienced MACE. Although the absence 
of any CAD excluded the occurrence of MACE, patients with the 
absence of coronary calcification demonstrated a cumulative event 
rate of 6% after 2 years. Accordingly, at least a 2-year event-free 
“warranty” period is given for patients with acute chest pain with no 
CAD defined by CCTA.36 By using the prognostic power of CCTA is 
a key to increase the risk–benefit ratio and the efficacy of CCTA in 
the acute chest pains setting.
Cost and Cost-Effectiveness of Coronary  
Computed Tomography Angiography in  
Acute Chest Pain Syndrome
Optimally, CCTA would reduce costs and provide more 
 cost-effective care in the triage of patients with acute chest pain. 
Overall, a significant reduction in length of stay, but no reduction 
in overall costs, was observed.31 However, a reduction of ED costs 
by 18% as compared with SOC ($2101 versus $2566) was observed 
(Table 1). In contrast, the costs during hospitalization were slightly 
increased using CCTA ($4026 versus $3874). Costs in the CCTA 
group were driven by a higher number of revascularizations due to 
the increased sensitivity of CCTA in detecting obstructive CAD.31 As 
previously discussed, it remains unclear whether this translates into 
an improvement in quality of life or health outcomes.
Previous work by Khare et al39 found that a triage strategy 
including CCTA would dominate other strategies, such as stress 
echocardiography or stress ECG, regarding its cost-effectiveness 
FIGURE 2.  Incorporation of CCTA into the triage of patients with acute chest pain syndrome. CCTA indicates coronary com-
puted tomography angiography; CT, computed tomography; ECG, electrocardiography; ED, emergency department.
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(incremental cost-effectiveness ratio was $29,738/quality adjusted 
life years (QALY) for CCTA, if compared with stress echocar-
diography, and $7332/QALY, if compared with the stress ECG). 
When comparing CCTA with SOC (eg, stress ECG), CCTA was 
more expensive for men when compared with women ($10,190 ver-
sus $6630), resulting in an incremental cost-effectiveness ratio of 
$6400/QALY for men and cost-savings for women.40
In summary, it seems that CCTA is a cost-effective alternative 
to stress testing. However, it may be more cost-effective in women 
than in men, due to the lower disease prevalence in women.
Appropriate Use of Coronary Computed 
Tomography Angiography
The appropriateness of a diagnostic test is strongly associ-
ated with the pretest probabilities and the change in probability by 
the test results. This has been demonstrated for CCTA in acute chest 
pain.41 Because of its high NPV, CCTA is most efficient in patients 
with low (2–10%) pretest likelihood for CAD, less in patients with 
intermediate, and very little in patients with high pretest probability 
(Fig. 3).16,30 Due to the low specificity of stress testing, CCTA is very 
efficient in patients with equivocal stress testing, as most of these 
patients do not have CAD. The current appropriateness criteria are 
explicitly defined in the consensus statement.25
STABLE CHEST PAIN SYNDROME
Epidemiology
Approximately 9 million people in the United States experi-
ence stable angina pectoris resulting from flow-limiting coronary 
artery stenoses.2 Classically, stable angina is a substernal chest tight-
ness that worsens with exertion and improves with rest. However, the 
diagnosis of stable angina may not be straightforward, as patients 
may present with atypical features. Stable angina is often seen as an 
early manifestation of CAD and is associated with an annual event 
rate of approximately 3% for developing an AMI.42,43
Stable angina is due to an imbalance between myocardial oxy-
gen demand and myocardial oxygen supply.44 With increasing oxygen 
demand in the setting of physical or emotional stress, the normal physi-
ological response is coronary vasodilatation, which results in increased 
myocardial blood flow.45 However, in the case of coronary atheroscle-
rotic disease, this vasodilatory capacity is reduced.45 Furthermore, an 
obstructive coronary stenosis of 75–95% of the  cross-sectional vessel 
area (or approximately 50% of the luminal diameter) is associated with 
a decrease in coronary flow and accordingly affects the myocardial 
oxygen supply.44 This link between coronary blood flow and narrowing 
of the coronary diameter provides the rationale for anatomical imag-
ing techniques such as CCTA. Notably, the degree of stenosis is not 
the only indicator of resistance to blood flow, as the entrance and exit 
angles, lesion length, and plaque morphology also affect downstream 
coronary flow.46 These considerations might explain the incremental 
value of functional imaging in the detection and characterization of 
CAD in patients with chronic stable chest pain.
The Immediate Value of Coronary  
Computed Tomography Angiography in  
Stable Chest Pain Syndromes
Diagnostic Accuracy
Compared with ICA as a reference, CCTA has consistently 
shown high diagnostic accuracy in detecting obstructive CAD. Many 
investigators believe that the clinical value of CCTA is its ability to 
rule out significant diseases due to the excellent sensitivity and NPV.
Few prospective multicenter studies of 64-slice or better mul-
tidetector CT technology are available with patients with stable chest 
pain (Table 2). Although the Coronary Artery Evaluation Using 
64-Row Multidetector CT Angiography (CORE64) trial47 and the 
study published by Meijboom et al48 included patients with known 
CAD and UA, respectively, the Assessment by Coronary Computed 
Tomographic Angiography of Individuals Undergoing Invasive Cor-
onary Angiography (ACCURACY) trial only included patients with 
stable chest pain without known CAD being referred to ICA.49 The 
Ontario Multidetector Computed Tomographic Coronary Angiog-
raphy study (OMCAS) included 2 groups of patients.50 One group 
consisted of symptomatic but stable patients, with an intermediate 
pretest probability, which were referred for ICA. The second group 
included asymptomatic patients, referred for ICA for nonchest pain 
evaluation (eg, congenital heart disease, aortic disease, and cardio-
myopathy). It should be noted that none of these studies excluded 
patients based on an elevated body mass index or calcium score. All 
vessels were included in the analysis, regardless of image quality. 
Accordingly, the prevalence of obstructive CAD varies significantly 
between studies from 25% to 68%.
The results from the ACCURACY and OMCAS trials may be 
most applicable due to their inclusion criteria.49,50 Both trials showed a 
sensitivity and specificity of more than 80% (Table 2). However, PPV 
and NPV were surprisingly different, probably due to the differences 
in CAD prevalence. In the ACCURACY trial,49 NPV was 99% and 
PPV 64%, whereas they were 78% and 97% in the OMCAS trial,50 
respectively. Similarly, the CORE64 trial found better PPV than 
NPV.47 Importantly, one major inconsistency between those trials is 
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In most studies, these unevaluable segments are classified as “posi-
tive” for obstructive CAD, whereas in the CORE64 trial, these seg-
ments were considered as “normal” for the purpose of analysis. It is 
possible and concerning that these published results therefore do not 
accurately reflect clinical scenarios. Clinically, readers are far more 
concerned to miss a significant lesion (“under-call”) rather than to 
overcall it. Therefore, translation or application of these results into 
clinical practice is challenging.
Hence, in clinical reality, CCTA will likely result in a low PPV, 
but a high NPV. A low PPV carries the risk of unnecessary invasive 
diagnostic procedures and interventions. Data from a broader range 
of real clinical readers with varying levels of experience are neces-
sary to assess the diagnostic accuracy of CCTA in real life. As an 
example, significantly lower diagnostic performance was observed 
in less experienced centers,50 a fact that highlights the necessity of 
standardization of training.
Change of Management
Data on the effect of CCTA on the clinical management of 
patients with stable chest pain are sparse. Therefore, large-scale, ran-
domized, comparative effectiveness trials such as the Prospective Mul-
ticenter Imaging Study for Evaluation of Chest Pain (PROMISE) and 
the Randomized Evaluation of Patients with Stable Angina Comparing 
Usage of Diagnostic Examinations (RESCUE) are underway to evalu-
ate the diagnostic differences between CCTA and other noninvasive 
imaging tests, such as myocardial perfusion scintigraphy or exercise 
ECG testing, see below for details. Today, most data are based on the 
international multicenter Coronary CT Angiography Evaluation for 
Clinical Outcomes: An International Multicenter registry (CONFIRM), 
which examined the referral patterns to ICA (with or without revascu-
larization) after CCTA.35 In 15,207 intermediate-risk patients from 8 
sites in 6 countries, the rates for ICA were low (<10%) in patients with 
no or nonobstructive CAD detected by CCTA. In contrast, nearly half 
of all patients with obstructive CAD by CCTA underwent subsequent 
ICA (44.3% for 1-vessel, 53.3% for 2-vessel, and 69.4% for 3-vessel 
obstructive CAD). The majority of ICA (79%) occurred within the first 
3 months after CCTA acquisition. In patients with obstructive CAD on 
CCTA, a marginal risk reduction for all-cause mortality was observed 
if an invasive coronary angiogram (with or without revascularization) 
was performed. These findings support the role of CCTA as a gate-
keeper for invasive diagnostics and interventions.
Furthermore, the detection of subclinical disease (ie, nonob-
structive CAD) by CCTA could guide primary care physicians to 
modify lifestyle and tailor preventative medical therapy. There are a 
few studies that have highlighted this potential role of CCTA. In the 
Study of Myocardial Perfusion and Coronary Anatomy Imaging Roles 
in Coronary Artery Disease registry with 1703 intermediate–high-risk 
patients who were examined for 90-day post-test rates of medication 
changes, post-test medical therapy intensification increased in pro-
portion to the degree of abnormal findings in imaging.51 Specifically, 
aspirin and lipid-lowering agent use was greater in patients under-
going CCTA versus other noninvasive imaging modalities, such as 
SPECT and positron emission tomography, likely related to the detec-
tion of nonobstructive CAD.51 More recently, Cheezum et al52 evalu-
ated a lower-risk symptomatic population and find that optimization 
of medical therapy based on CCTA-detected CAD resulted in a favor-
able impact on blood pressure and lipid profiles. Similarly, Ovrehus 
et al53 showed in a cohort of 1055 consecutive patients with suspected 
stable angina pectoris, a decrease in antiplatelet therapy use in patients 
with no CAD, and an increase in lipid-lowering agents and antiplatelet 
therapy in patients with CAD, as determined by CCTA. It is conceiv-
able that these changes of risk factors, secondary to  CCTA-guided 
medical therapy adjustments, may ultimately improve patient out-
comes. The current use of information, based on CCTA to tailor ther-
apy, is not mandated by guideline recommendations, and prospective 
randomized trials are warranted to justify change in therapy.
The Long-Term Value of Coronary Computed 
Tomography Angiography in Stable Chest Pain 
Syndrome
Prognostic Information
The prognostic value of CCTA in patients with stable chest 
pain has been evaluated in several small studies and summarized thus 
far in 3 meta-analyses.54–56 In addition, several studies were based 
on the international multicenter CONFIRM registry.57–61 A normal 
CCTA was associated with an annualized event rate of 0.17–0.40%, 
based on different meta-analyses54–56 and the CONFIRM registry.59 
This large range in annualized event rate is explained by the fact that 
some studies, such as the CONFIRM registry, include only all-cause 
mortality instead of MACE as an endpoint.59,62,63 This underscores 
the prognostic value of the high NPV of CCTA, particularly when 
compared with the prognosis after normal ICA or stress testing.64–66
The length of the event-free “warranty period” is unclear 
after a CCTA reveals no CAD. In a subanalysis of the CONFIRM 














Budoff et al49 
(ACCURACY)
2008 230/16 No known CAD, stable chest 
pain, or abnormal functional 
stress testing
57 ± 10 41 25 95% (85–99%) 83% (76–88%)
Meijboom et al48 2008 360/3 No known CAD, presenting 
with stable, or acute chest 
pain
60 ± 6 32 64 99% (98–100%) 64% (55–73%)
Miller et al47 (CORE64) 2008 291/9 Symptomatic patients with 
suspected or known CAD
60 ± 6 26 56 85% (79–90%) 90% (83–94%)
Chow et al50 (OMCAS) 2011 117*/4 Chest pain with intermediate 
probability of significant 
CAD
60 ± 10 40 61 81% (72–90%) 97% (86–100%)
In all studies, presence of stenosis by CCTA was compared with significant CAD as determined by invasive angiography.
*Subgroup of symptomatic patients.
ACCURACY indicates Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography; CAD, coronary artery disease; 
CCTA, coronary computed tomography angiography; CI, confidence interval; CORE64, Coronary Artery Evaluation Using 64-Row Multidetector CT Angiography; OMCAS, Ontario 
Multidetector Computed Tomographic Coronary Angiography Study.
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more than 4-year follow-up (1816 patients).59 Based on these data, 
4 years seems like a reasonable event-free warranty period to ascribe 
to CCTA, but further studies are needed to evaluate prognosis for 
endpoints beyond all-cause mortality, such as AMI and UA.
In contrast, the annualized event rate for patients with obstruc-
tive disease detected by CCTA ranged from 9% to 16%, driven 
predominantly by coronary revascularizations.54–56 After exclud-
ing revascularizations, obstructive CAD, as determined by CCTA, 
remained a significant predictor for a worse outcome (annualized 
rate: 3.2% for death or MI, 6.4% for MACE excluding revasculariza-
tion).54,56 If the endpoint is restricted to all-cause mortality, as shown 
in the CONFIRM registry, annualized death rates ranged from 2.9% 
to 4.95%, depending on whether a single vascular territory stenosis 
or a high-risk CAD profile, consisting of left main stenosis and/or 
2- to 3-vessel stenosis, was present.60 Several authors showed that the 
prognostic value of obstructive CAD was dependent on the degree of 
stenosis (hazard rate ratio, 2.60 and 3.13 in patients with more than 
50% and 70% stenoses) or the complaint of diabetes mellitus (haz-
ard rate ratio, 13.25 versus 9.25 for 3-vessel stenosis, respectively).59 
Notably, a significant coronary stenosis (>50%) can be present in 
patients with a calcium score of zero (3.5% prevalence in more than 
5000 patients with zero calcium scoring).61 In those patients (obstruc-
tive CAD, but zero calcium score), 3.9% (7 of 177) died during the 
follow-up period of up to 1500 days.
Nonobstructive plaque (<50% stenosis) derived by CCTA is 
associated with an annualized MACE rate of 1.41% and mortality 
event rate of 0.74–1.99%.56,60 Interestingly, the CONFIRM registry 
showed a similar mortality risk between patients with nonobstructive 
CAD and those with 1-vessel obstructive CAD (hazard ratio, 1.62 
versus 1.75, respectively).59 This points out the value of identifying 
the extent of CAD in addition to severity and is supported by further 
analyses showing dose–response relationships for increased hazards 
of death in patients with 1-vessel, 2-vessel, and 3-vessel disease.59 In 
general, CAD can be quantified either manually, with a per-segment 
analysis, or using semi-automated tools. Regardless of methodology, 
increased risks for future events and mortality were observed with a 
larger extent of CAD.54,59 In addition, the location of obstructive CAD 
matters, as stenoses in the left main and proximal left anterior descend-
ing coronary arteries were associated with increasing event rates.54,59,60 
Accordingly, the Duke Prognostic CAD index was modified to account 
for stenosis severity, extent, and location, providing improved predic-
tive value for mortality.62 Similarly, a new grading system is being 
developed, based on the CONFIRM registry, incorporating traditional 
risk factors with plaque severity, extent, location, and morphology.
Plaque morphology has been widely studied for its predic-
tive value. Although several studies showed that partially calcified 
plaque yielded a higher risk for developing events, existing data 
are inconsistent.67–69 To date, in most studies, the plaque character-
ization is limited to classification, such as noncalcified, calcified, 
and partially calcified (mixed plaque), which may be not sufficient 
to describe high-risk plaque morphology and hence lead to these 
inconsistent findings.
All these findings must be interpreted carefully, consid-
ering several limitations. Most studies included late coronary 
revascularization (>90 days) as part of the definition of MACE. 
However, this endpoint may be directly related to the results of 
CCTA findings. There is a “verification bias” with respect to taking 
a patient with indeterminate and moderate–severe stenosis from 
CCTA to invasive angiography for finding confirmation. In stud-
ies with all-cause mortality set as an endpoint, causality between 
CCTA findings and endpoint may not be given, considering the 
recent data from the Framingham Heart Study showing that the 
proportion of true  cardiovascular-associated death is decreas-
ing and cardiac death only presents 40% of all deaths.70 Finally, 
large heterogeneity exists across almost every important variables, 
that is, pretest probability, inclusion of known CAD, inclusion of 
minorities, inclusion of younger patients, CAD reporting schemes 
(eg, >50% or >70% luminal narrowing for obstructive CAD). 
These heterogeneities challenge the generalization of conclusions 
and highlight the difficulties in conducting high-quality, valuable 
prognostic studies. Accordingly, more evidence on the prognostic 
value of coronary CCTA has been demanded by the Centers for 
Medicare/Medicaid Services and the most recent CCTA expert 
consensus statements.46,71
Quality of Life
Few studies in patients with stable chest pain have focused on 
quality of life. A recent study by Min et al,72 where 180 patients with 
stable chest pain with suspected CAD were randomized to CCTA or 
SPECT, found no difference in the health status as assessed by the 
Seattle Angina Questionnaire. Further research in this field is needed 
to determine whether patients benefit differently regarding their qual-
ity of life from different imaging modalities.
Cost and Cost-Effectiveness of Coronary  
Computed Tomography Angiography in  
Stable Chest Pain Syndrome
Cost-effectiveness in patients with stable angina is dependent 
of test characteristics and pretest probability of CAD.73–75 Depending 
on the assumed willingness-to-pay, and other assumptions, CCTA 
cost-effectiveness was compared with invasive angiography for pre-
test probability between 37% and 49%,73–75 with higher pretest prob-
ability values for men than for women.74
Based on the ACCURACY study, Min et al76 showed that the 
combination of CCTA with adjacent SPECT acquisition resulted 
in the lowest cost per correct diagnosis ($1770 per patient). CCTA, 
followed by invasive angiography, was more effective and hence 
resulted in a more favorable incremental cost-effectiveness ratio and 
remained the most cost-effective strategy, especially in a long-term 
perspective. It should be noted that those calculated data are based 
on a pretest probability of 30% for obstructive CAD. A comparable 
study by Ladapo et al,77 with a typical case of a 55-year-old female 
or male patient with atypical chest pain and a pretest probability of 
30% and 70%, respectively, showed that the use of CCTA followed 
by stress ECG in male patients was the most cost-effective approach, 
with an incremental cost-effective ratio of $26,200/QALY versus 
$35,000/QALY for female patients. However, women received the 
most favorable health outcome per unit cost when receiving the 
combined CCTA and stress ECG strategy. Analyzing real-world 
data, Medicare data showed a decrease of CAD-related costs after 
9 months, if patients with low risk for adverse cardiac events under-
went CCTA rather than SPECT.78
Results regarding costs and outcomes from the major, cur-
rently recruiting, randomized, controlled trial in patients with sta-
ble chest pain (eg, PROMISE, RESCUE, and International Study 
of Comparative Health Effectiveness with Medical and Invasive 
Approaches) must be awaited before valid conclusions can be made 
regarding the cost-effectiveness of CCTA in this population.
RADIATION DOSE OF CORONARY  
COMPUTED TOMOGRAPHY ANGIOGRAPHY IN 
CHEST PAIN EVALUATION
One of the major concerns using CCTA has been patient 
radiation exposure.79,80 Over the last several years, aggressive efforts 
have been made by the cardiovascular imaging community to lower 
the effective radiation dose by optimizing acquisition protocols. 
These efforts, plus improvements in technology, have resulted in a 
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significant reduction of radiation dose, without the need to sacrifice 
image quality.81–84 Key developments in the reduction of radiation, 
such as iterative image reconstruction algorithms (see below), and 
prospective gating protocols, play an important role.
Prospective ECG-Triggered Axial Acquisition
This technique is also referred to as “step-and-shoot” imaging, 
in which the scanner table moves in a step-wise manner for every 
other heart beat until the full scan length is acquired. At each step, 
radiation exposure is limited to only one phase of the cardiac cycle 
although “padding” can be used around this phase, resulting in sub-
stantially lower effective radiation dose (approximately 3–4 mSv), 
but requires stable and slow heart rhythms.85–87
Prospective ECG-Triggered, High-Pitch Acquisition
This relatively new acquisition technique relies on a fast table 
speed (high pitch), allowing the acquisition of the entire heart in 0.6 
seconds. Given the speed of acquisition, a breath hold is not even 
required and radiation exposure can be reduced to approximately 1 
mSv for a coronary acquisition.88,89
CURRENT DEVELOPMENTS IN  
CORONARY COMPUTED TOMOGRAPHY 
ANGIOGRAPHY TECHNIQUES
Several novel developments have emerged over the last few 
years, promising an improvement of CCTA. Those with particularly 
strong potential include iterative image reconstruction algorithms 
and computational algorithms predicting FFR.
In comparison with the common filtered-back projection 
method for image reconstruction, iterative reconstruction algo-
rithms synthesize raw data, which are iteratively corrected and 
compared with acquired raw data.90 The largest benefit has been 
observed regarding the reduction in image noise and improve-
ment in image quality.91 Accordingly, tube voltage (and therefore 
effective radiation dose) can be further reduced without altering 
the diagnostic quality of the scan.92,93 Additional benefits, such 
as decreased blooming artifact from coronary calcification, have 
been observed, but the implications for clinical practice need to 
be evaluated.
Based on a novel computation algorithm, FFR can be pre-
dicted based on any regularly acquired CCTA scan. Recently, FFR 
has increased in popularity in invasive cardiology after large ran-
domized control trials have shown improved clinical outcomes 
for FFR-guided therapy.94,95 Based on CCTA datasets, a calculated 
FFR (CT-FFR) was evaluated in the Determination of Fractional 
Flow Reserve by Anatomic Computed Tomographic Angiography 
(DeFACTO) study, a multicenter observational cohort trial.96 This 
study compared a CT-FFR of 252 patients with the invasively mea-
sured FFR, finding that CT-FFR is a significantly better predictor 
for FFR when compared with the presence and severity of stenosis 
detected by CCTA. Although the correlation of CT-FFR with inva-
sively measured FFR was good on a per-patient level, it was lower on 
a per-vessel level, which is where CT-FFR could potentially provide 
its greatest value.2 However, the per-vessel perspective may be more 
relevant for a subsequently testing strategy.
Although this is quite promising and would enable CCTA to 
provide more than morphological information, the use of this novel 
technology needs to be analyzed in real-world practice. CT-FFR is 
not yet approved by the Food and Drug Administration. Furthermore, 
it should be determined whether CT-FFR has any ability to improve 
resource usage and clinical outcomes for patients with chest pain. 
Because the calculation of CT-FFR is currently a time-consuming 
endeavor, this novel algorithm may be more suitable for patients with 
stable chest pain.
SUMMARY AND FUTURE DIRECTIONS
For patients with acute or stable chest pain syndromes, CCTA 
is a safe and effective diagnostic modality. The strength of CCTA is 
its high NPV to rule out CAD, which carries independent prognos-
tic value for short- and long-term coronary events, better than any 
individual or combination of risk factors or any other diagnostic test.
Early CCTA is a viable alternative to stress testing in the tri-
age of patients with an acute chest pain syndrome. By using CCTA, 
the length of hospital stay is reduced dramatically, allowing for a 
faster yet safe discharge from the ED or chest pain unit. To improve 
cost-effectiveness, biomarkers may be an efficient gatekeeper for fur-
ther testing. There is further need to establish the potential long-term 
health and economic benefits of CCTA in acute chest pain, including 
those of percutaneous coronary intervention resulting from CCTA. 
Similarly, initial evidence of CCTA-derived benefits in patients with 
stable chest pain must be extended.
For patients with stable chest pain, the clinical benefit of 
CCTA is less established. Two large multicenter, randomized, con-
trolled trials are currently being conducted: the PROMISE trial and 
the RESCUE trial. The PROMISE trial is targeting an enrollment of 
10,000 patients with stable chest pain from approximately 200 U.S. 
sites and will compare CCTA-based anatomical testing with func-
tional testing, including exercise tolerance testing and stress nuclear 
imaging. The primary endpoint of the study is frequency of death, 
MI, and/or major periprocedural complications, applying each diag-
nostic strategy. Furthermore, PROMISE trial will address questions 
regarding the effect of CCTA on medical costs, resource usage, 
 cost-effectiveness, and quality of life. The RESCUE trial is targeting 
recruitment of 4300 patients with stable chest pain from 80 institu-
tions internationally. Patients are randomized to CCTA or nuclear 
stress testing and followed for a composite endpoint of MACE, 
including revascularization and cross-over to revascularization, over 
a period of up to 2 years. Both trials will be pivotal in guiding our 
use of CCTA in the setting of patients with stable, chronic chest pain.
With the usage of improved technology and optimized scan 
protocols, the average reported radiation dose for CCTA is compa-
rable with or even below other diagnostic testing procedures, such as 
nuclear stress testing or invasive angiography. A further reduction of 
the radiation dose is feasible and may encourage the clinical use of 
CCTA over other imaging modalities for the evaluation of patients 
with both acute and stable chest pain.
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